The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...

The biotech engaged with the FDA on alternative pathways to approval after seeing safety and efficacy data from the phase 1/2 ...

Shares in Sangamo Therapeutics (Nasdaq: SGMO) surged around 40% on Tuesday, following the announcement that the US Food and ...

Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) and keeping the ...

Sangamo (SGMO) announced the outcome of a recent interaction with the FDA, providing a clear regulatory pathway to accelerated approval for ...

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow. Pfizer and Sangamo are hoping for a faster trajectory ...

Marshall Wace LLP increased its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Free Report) by 56.3% in the ...

a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Receive News & Ratings for Sangamo ...

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company pioneering CRISPR-based programmable genome medicines, today announced the appointment of Dr. TJ Cradick as Chief ...